CXCR3 and neoplasm: Other studies have shown that active CD26 cleaves the chemokine CXCL10 turning it into an antagonist for its cognate CXCR3 receptor, effectively disrupting the chemotaxis that otherwise recruits CXCR3+ effector T-cells to the tumours [45].